Skip to main content

Featured

How Crypto is Taxed in Canada — What CRA Expects From You (2026 Guide)

  Published: April 2026 | Reading time: 11 min | Category: Taxes, Investing, Personal Finance A lot of Canadians still believe cryptocurrency exists in a tax-free grey zone. It does not. The Canada Revenue Agency is very clear on this: crypto is taxable, every transaction counts, and CRA has been aggressively pursuing crypto investors who don't report correctly. If you've bought, sold, traded, or earned any cryptocurrency in Canada — Bitcoin, Ethereum, Solana, or anything else — this guide explains exactly what CRA expects from you, what counts as a taxable event, and how to reduce your tax bill legally. The CRA's Official Position on Crypto The CRA treats cryptocurrency as a commodity , not a currency. This is a critical distinction. It means: Crypto is subject to either capital gains tax or income tax depending on how you use it Every time you dispose of crypto — sell it, trade it, spend it, or give it away — you trigger a taxable event Simply holding cryp...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment